In the last trading session, 1.63 million shares of the Soleno Therapeutics Inc (NASDAQ:SLNO) were traded, and its beta was -2.12. Most recently the company’s share price was $50.05, and it changed around -$0.09 or -0.18% from the last close, which brings the market valuation of the company to $2.30B. SLNO currently trades at a discount to its 52-week high of $60.92, offering almost -21.72% off that amount. The share price’s 52-week low was $36.61, which indicates that the current value has risen by an impressive 26.85% since then. We note from Soleno Therapeutics Inc’s average daily trading volume that its 10-day average is 0.84 million shares, with the 3-month average coming to 523.85K.

Soleno Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.11. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended SLNO as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Soleno Therapeutics Inc is expected to report earnings per share of 0 for the current quarter.

Soleno Therapeutics Inc (NASDAQ:SLNO) trade information

Instantly SLNO has showed a red trend with a performance of -0.18% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 51.88 on recent trading dayincreased the stock’s daily price by 3.53%. The company’s shares are currently up 11.35% year-to-date, but still down -0.12% over the last five days. On the other hand, Soleno Therapeutics Inc (NASDAQ:SLNO) is 11.20% up in the 30-day period. We can see from the shorts that 4.81 million shares have been sold at a short interest cover period of 11.8 day(s).

The consensus price target as assigned by Wall Street analysts is $72, which translates to bulls needing to increase their stock price by 30.49% from its current value. Analyst projections state that SLNO is forecast to be at a low of $70 and a high of $74.

8 analysts expect Soleno Therapeutics Inc to make 2.81M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 20.19%.

SLNO Dividends

Soleno Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-26.

Soleno Therapeutics Inc (NASDAQ:SLNO)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 2.93% of Soleno Therapeutics Inc shares, and 113.72% of them are in the hands of institutional investors. The stock currently has a share float of 117.16%. Soleno Therapeutics Inc stock is held by 219.0 institutions, with VIVO CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 18.9401% of the shares, which is about 7.32 million shares worth $298.53 million.

CARLYLE GROUP INC., with 10.5395% or 4.07 million shares worth $166.36 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and Janus Henderson Global Life Sciences Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.13 shares worth $56.48 million, making up 2.46% of all outstanding shares. On the other hand, Janus Henderson Global Life Sciences Fund held roughly 933.3 shares worth around $46.71 million, which represents about 2.04% of the total shares outstanding.